A Phase 1/2 clinical trial testing AAV-GAD, an investigational gene therapy being developed by MeiraGTx for Parkinson’s disease, is expected to be fully enrolled before the end of the year, the company announced in a press release. The placebo-controlled trial (NCT05603312), which began dosing last…
News
A five-year project funded by a $3.9 million National Institutes of Health (NIH) research grant will study how team-based palliative care might lead to better health services and ease disparities in Parkinson’s disease and disease-related dementia care. Palliative care focuses on improving the quality of life for individuals with…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $10 million grant to Octave Biosciences to advance the development and validation of a protein biomarker panel assay for Parkinson’s disease. A biomarker assay for multiple proteins could offer a better tool to monitor and…
In what is being touted as an “historic” act, the spouse and children of qualified veterans with Parkinson’s disease, or those with the disease themselves, are invited to apply for assistance under the Camp Lejeune Family Member Program (CLFMP) run by the U.S. Department of Veteran Affairs…
Altered levels of proteins in the amygdala, the brain region involved in memory, decision-making, and emotional responses, were discovered in Parkinson’s disease patients, a study reports. These changes in the amygdala were associated with synapses, the minute gaps between nerve cells through which impulses pass, allowing the cells to…
ATH434, an experimental therapy that’s currently in clinical trials for a type of atypical parkinsonism known as multiple system atrophy (MSA), has antioxidant activities that may protect mitochondria and contribute to its therapeutic effects. Data supporting its actions were presented this month at the Society for Neuroscience in Washington,…
Scientists in India are conducting a clinical trial to test whether regularly participating in yoga can slow the progression of Parkinson’s disease. The study, which has been running since early 2022, is ongoing with researchers expecting to continue enrolling new patients into the first few months of 2024. The…
Researchers have discovered a new early-onset movement disorder associated with mutations in the ACBD6 gene, and several symptoms are similar to those observed in Parkinson’s disease. Genetic sequencing across more than two dozen unrelated families uncovered disease-causing mutations in the gene that were linked to a distinct neurodevelopmental disease that has…
IntelGenx has won approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2 trial on Montelukast Versafilm, its proprietary oral thin film formulation, in people with Parkinson’s disease. The Phase 2 MONTPARK multicenter study will investigate the effectiveness of oral high-dose Montelukast on the progression…
The Parkinson’s Foundation is calling for applications for $1 million in 2024 community grants, with funding supporting health, wellness, and educational programs that address unmet needs in local Parkinson’s disease communities in the U.S. The application deadline is Jan. 31; recipients will be announced in July. The…
Recent Posts
- New report shows Parkinson’s costs surpass $82 billion in US in 2024
- Pushing forward this Parkinson’s Awareness Month with boldness, grace
- Personalized DBS for Parkinson’s may result from brain study in China
- Fecal transplants ease motor symptoms in early Parkinson’s: Study
- ‘Moving Day, A Walk for Parkinson’s’ marks 15th year with events across US